U-47700

6Node page

what any key link opens

psx:substance/u-47700/claim/10ebd684-d124-4ff0-a828-3d43d06217a4

claim2026-07-18workinginconclusive

derived from · upstream

usedDARK Classics in Chemical Neuroscience: U-47700psx:substance/u-47700/src/doi:10.1021/acschemneuro.0c00330

feeds · downstream

informed_bysection/history.full@1psx:substance/u-47700/section/history.full@1

psx:substance/u-47700/claim/10ebd684-d124-4ff0-a828-3d43d06217a4
├─ used  src/doi:10.1021/acschemneuro.0c00330  DARK Classics in Chemical Neuroscience: U-47700
  ├─ informed_by  claim/0cdf81b9-3303-4c98-be1f-24efcac4abe1  Claim in history — inconclusive  working
  ├─ informed_by  claim/49aa0ba3-21bb-49e1-b9f1-c2c0ba8bf3c1  Claim in history — inconclusive  working
  ├─ informed_by  claim/7c3f195f-f523-44a3-858e-b043a8fddb0e  Claim in history — inconclusive  working
  ├─ informed_by  claim/786cb23d-5a5a-4a00-ae3b-f8e5ce41ba91  Claim in history — inconclusive  working
  ├─ informed_by  claim/1aa7534b-b6a0-43c7-8340-694fbaae9764  Claim in history — inconclusive  working
  ├─ informed_by  claim/28107ce5-f6aa-4e1a-8be7-fac10af7aa7c  Claim in history — inconclusive  working
  ├─ informed_by  claim/76b3bc3d-849d-49b0-ae30-9477f4f69feb  Claim in history — inconclusive  working
  ├─ informed_by  claim/77cb43cf-b4dd-41e8-9eab-4bdfba54890a  Claim in history — inconclusive  working
    ├─ used  src/doi:10.1016/j.neuropharm.2020.108195  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats
    ├─ used  src/doi:10.1016/j.neuropharm.2017.08.016  Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace
    ├─ used  src/pmid:27590036  Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC-MS/MS in Postmortem Casework
    ├─ used  src/doi:10.1016/j.forsciint.2019.04.010  Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug
    ├─ used  src/doi:10.1016/j.forsciint.2019.04.030  Toxic lifespan of the synthetic opioid U-47,700 in Finland verified by re-analysis of UPLC-TOF-MS data
    ├─ used  src/doi:10.3389/fpsyt.2017.00110  An Expanding World of Novel Psychoactive Substances: Opioids
    ├─ used  src/url:45a13c74420c2964  DEA Schedules Deadly Synthetic Drug U-47700 - Press Release
    ├─ used  src/pmid:27905978  Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I. Final order
    ├─ used  src/url:3fdc70b47ed3951e  UNODC Substance Details: U-47700 (CID 237db0fd)
    ├─ used  src/url:2f5b38eeb1243fa6  Circular 008/2017: A change to the Misuse of Drugs Act 1971 to control U-47700
    ├─ used  src/url:05303be8251da6e6  Canada Gazette: Regulations Amending Schedule I to the Controlled Drugs and Substances Act (U-47700)
    ├─ used  src/doi:10.3389/fphar.2023.1219985  Development of a vaccine against the synthetic opioid U-47700
    ├─ used  src/doi:10.1007/s12024-018-0018-3  Another fatal case related to the recreational abuse of U-47700
    ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
    ├─ used  src/doi:10.1016/j.taap.2025.117352  Rat-to-human PBPK model of U-47700: Unveiling pharmacokinetic risks of a synthetic opioid through interspecies extrapolation
    ├─ used  src/doi:10.1002/dta.2228  Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users
    ├─ used  src/doi:10.1007/s00414-018-1969-3  Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700
    ├─ used  src/doi:10.1002/ardp.202300256  In silico characterization of ligand-receptor interactions for U-47700, N,N-didesmethyl-U-47700, U-50488 at mu- and kappa-opioid receptors
    ├─ used  src/doi:10.1007/s00204-021-03207-9  Characterization of recent non-fentanyl synthetic opioids via three different in vitro mu-opioid receptor activation assays
    ├─ used  src/doi:10.1093/jat/bkw124  A Fatality Related to the Synthetic Opioid U-47700: Postmortem Concentration Distribution
    ├─ used  src/doi:10.15585/mmwr.mm6643e1  Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016.
    ├─ used  src/doi:10.1093/jat/bkz018  Challenges Related to Three Cases of Fatal Intoxication to Multiple Novel Synthetic Opioids
    ├─ used  src/doi:10.1093/jat/bkx060  Multiple Drug-Toxicity Involving Novel Psychoactive Substances, 3-Fluorophenmetrazine and U-47700
    ├─ used  src/doi:10.1111/1556-4029.13822  To Test or Not To Test?: The Value of Toxicology in a Delayed Overdose Death
    ├─ used  src/doi:10.1080/15563650.2016.1209764  Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid class
    ├─ used  src/doi:10.1002/dta.2393  Analysis of fentanyl analogs and novel synthetic opioids in blood, serum/plasma, and urine in forensic casework
    ├─ used  src/doi:10.1016/j.forsciint.2020.110437  Multiplex detection of 14 fentanyl analogues and U-47700 in biological samples: Application to a panel of French hospitalized patients
    ├─ used  src/doi:10.1007/s40262-024-01355-6  Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
    ├─ derived_from  gen/8d17dfc9-a353-41c5-a698-2e195472be12  Generation — pipeline-v5
    ├─ generated_by  pub/34b1532c-3460-4f78-ba6b-65cf0090b547  Publication — backfill
      ├─ used  search/0fdd6f76-db68-4fc0-88af-51e6062cb94d  Searched PubChem for "U-47700"
      └─ used  search/99e5825d-048a-44d1-903c-bb5857e7f11a  Searched PubMed for "U-47700 opioid pharmacology receptor binding"
├─ informed_by  section/history.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/639de316-4a4c-47e0-8dde-a1d6cf69a60d  Claim in chemistry — inconclusive  working
  ├─ used  claim/fd18e6b5-9e33-4edc-b093-660070be1284  Claim in summary — inconclusive  working
  ├─ used  claim/faca3173-0dc4-4096-9f38-111279fe7971  Claim in safety — inconclusive  working
  ├─ used  claim/9d00a6b8-6f2c-4b45-8a60-0848c11f0db5  Claim in history — inconclusive  working
  ├─ used  claim/075e6a77-8e30-4e58-999e-b4c29c193270  Claim in history — inconclusive  working
  ├─ used  claim/b0214f81-36ce-4b3e-b1c9-380759280f94  Claim in history — inconclusive  working
  ├─ used  claim/df4c83e1-25f3-4076-be5d-98c92889aa79  Claim in history — inconclusive  working
  ├─ used  claim/12d83cd2-0201-469b-9ecb-dcf27c68057f  Claim in history — inconclusive  working
  ├─ used  claim/124f6312-4a05-4ded-9dc0-0ef1a7ef461d  Claim in history — inconclusive  working
  ├─ used  claim/ad197c3f-fc48-403d-abd4-5d6ccc90e384  Claim in history — inconclusive  working
  ├─ used  claim/f1756314-ab76-4a90-b756-4fe7b8920e85  Claim in chemistry — inconclusive  working
  ├─ used  claim/3f26a3ab-6827-47cf-a216-7a4283678f9d  Claim in summary — inconclusive  working
  ├─ used  claim/cf0781ab-5a3a-4a6e-83ef-deb76ab76060  Claim in safety — inconclusive  working
  ├─ used  claim/94c804e2-b567-4487-9904-35503cd7c25d  Claim in history — inconclusive  working
  ├─ used  claim/b2e674cc-e28d-40a2-8fcb-8936dbb13b73  Claim in history — inconclusive  working
  ├─ used  claim/eaa05c23-f739-4e4f-8e11-59020e0c0c8c  Claim in history — inconclusive  working
  ├─ used  claim/6787b54e-cef5-479b-a1d2-431fd98cda00  Claim in history — inconclusive  working
  ├─ used  claim/350f1f45-14b5-428f-93dc-8507ba77e9b8  Claim in history — inconclusive  working
  ├─ used  claim/a90d519b-3884-45ea-8205-091bc671d2fb  Claim in history — inconclusive  working
  ├─ used  claim/0b2d8268-0509-4187-823d-8eef8b28940a  Claim in chemistry — inconclusive  working
  ├─ used  claim/c018df7c-e166-48a4-be88-976b1775c502  Claim in chemistry — inconclusive  working
    ├─ derived_from  issue/notice@de80e261c2b4  Issued notice
    ├─ derived_from  issue/info_card@0335bca422f8  Issued info_card
    ├─ derived_from  issue/emergency@f85b2d2362c9  Issued emergency
    ├─ derived_from  issue/info_card@f4a704e0ac55  Issued info_card
    ├─ informed_by  section/chemistry.full@1
    ├─ informed_by  section/summary.full@1
    ├─ informed_by  section/safety.full@1
      ├─ used  claim/9e750add-f70c-4957-a6fc-919bd39a7562  Claim in summary — inconclusive  working
      ├─ used  claim/cf24ad55-c1c1-4d65-afd7-27a78aeea4c8  Claim in summary — inconclusive  working
      ├─ used  claim/2b96e0db-0b7f-45ea-97e3-91e61f3d2fea  Claim in pharmacology — inconclusive  working
      ├─ used  claim/0874088f-a729-4e3a-9412-35f9c19bb181  Claim in pharmacology — inconclusive  working
      ├─ used  claim/4198a89d-0cea-4123-a531-0788308ca411  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/e6242d0b-df88-47bb-bf2c-4056e87399eb  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/cc47f17b-ac86-4553-95d6-54134c678c5c  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/dae74ae0-51c4-42cc-977b-5842c94c4043  Claim in neuroscience — inconclusive  working
      ├─ used  claim/c572fd1f-a0f5-4008-9c2d-1ebc9f4a154e  Claim in chemistry — inconclusive  working
      ├─ used  claim/0ecdf82e-0688-402b-9893-3bc625a0e7fc  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/cd562347-6b1c-4e32-919f-c493028ade0b  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/a3360cf5-23c4-44bb-acd1-438c3727c3b8  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/2baa130c-c854-4ce0-b61a-e002e8502203  Claim in summary — inconclusive  working
      ├─ used  claim/62cebd60-f17a-44c3-91d1-0be25b097be5  Claim in summary — inconclusive  working
      ├─ used  claim/ff8cc5a4-953e-4184-99cd-a79183aec881  Claim in pharmacology — inconclusive  working
      ├─ used  claim/2e940e1c-827d-4589-ab92-b57787b2d3a7  Claim in pharmacology — inconclusive  working
      ├─ used  claim/e215754c-197b-4092-9331-b6669f5f55d2  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/52cc10f2-db10-480c-b965-86187466f4b2  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/84a49df0-3a78-491d-9509-a7173d5aa077  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/070dd308-33a0-4c6f-a7fb-f7a002c97588  Claim in neuroscience — inconclusive  working
      ├─ used  claim/6172108c-0125-447a-8473-64ba479ad379  Claim in chemistry — inconclusive  working
      ├─ used  claim/96174554-9ef6-4f84-b8cf-8aff2ac11089  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/9341c11c-6378-4c16-a30d-1c29bebf2c64  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/34012fd7-5f31-4c15-ac0a-767c550ebb50  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/41c20a0c-34ca-4b29-99b2-eb863a76d8dd  Claim in safety — inconclusive  working
      ├─ used  claim/12603347-efe6-4a7d-a6a9-d31a6dc7c3ce  Claim in summary — inconclusive  working
      ├─ used  claim/98f9974e-d937-4cd4-ad21-eb7af89247af  Claim in pharmacology — inconclusive  working
      ├─ used  claim/c39346ec-41f5-4c5e-86f5-164fac993030  Claim in pharmacology — inconclusive  working
      ├─ used  claim/0d667b69-cc08-4f12-9074-63bed43d442c  Claim in summary — partially_supported
      ├─ used  claim/d4c5ba90-1609-4f3f-b3a8-200a8efff177  Claim in pharmacology — partially_supported
      ├─ used  claim/01f535d1-8fa6-46e8-837f-ec4c9c6c718d  Claim in pharmacology — inconclusive  working
      ├─ used  claim/94f125f0-989c-4eef-a15b-d8907a15c821  Claim in safety — inconclusive  working
      ├─ used  claim/6b563319-68b3-468c-b760-2d2c13226619  Claim in summary — inconclusive  working
      ├─ used  claim/82ea5853-8bcf-4a95-a160-cfcfe0c40e49  Claim in safety — inconclusive  working
      ├─ used  claim/3e95107d-cf25-487c-8bc8-577788e9db39  Claim in safety — inconclusive  working
      ├─ used  claim/6c1c9c74-d508-4cef-98cb-95f3d26ead22  Claim in summary — inconclusive  working
      ├─ used  claim/4208a4ac-ab66-47a2-b0b4-ef8da894f523  Claim in safety — inconclusive  working
      ├─ used  claim/a5ba02f5-ff0e-40f7-90db-810f505d73a3  Claim in safety — inconclusive  working
      ├─ used  claim/31aa2c4a-fe98-4935-86e4-d4cebb1c726f  Claim in summary — inconclusive  working
      ├─ used  claim/2965eb37-1ebf-40f7-a05d-7a6231d8659c  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/d9c8c9e4-04ce-461b-bdcc-209825034237  Claim in safety — inconclusive  working
      ├─ used  claim/46101a31-6476-4a75-903e-af6bdd5bc225  Claim in safety — inconclusive  working
      ├─ used  claim/43954055-5d51-4310-8d0a-a93d42485ee2  Claim in summary — inconclusive  working
      ├─ used  claim/c13c1c20-f72b-4365-9e6a-4a4b9f0b8ab2  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/5b2afa0a-7736-499c-b993-4ba30681e49e  Claim in safety — inconclusive  working
      ├─ used  claim/7c2133ec-027b-4a87-98c6-3301cc8ef40f  Claim in safety — inconclusive  working
      ├─ used  claim/067aea70-601f-417c-aff3-b66e2b1318a6  Claim in safety — inconclusive  working
      ├─ used  claim/a6a51c5c-0089-4c8e-9046-4408b4c0e34a  Claim in safety — inconclusive  working
      ├─ used  claim/506ace93-f23f-4b3f-a663-fc27faabdac5  Claim in safety — inconclusive  working
      ├─ used  claim/4e7aa685-6d92-46dd-b3f5-1ee209bd70cc  Claim in safety — inconclusive  working
      ├─ used  claim/9818118b-8312-4643-8cc0-1e4c43cf1721  Claim in safety — inconclusive  working
      ├─ used  claim/bc8377d1-0eb2-4ec5-9d84-11803dc7192f  Claim in pharmacology — inconclusive  working
      ├─ used  claim/0df647d5-4396-4bd3-a331-36ab4f39d4ed  Claim in neuroscience — inconclusive  working
      ├─ used  claim/b43bbe98-e18d-431b-b0d1-6a5ba7aa5eec  Claim in pharmacology — inconclusive  working
      ├─ used  claim/80d09730-0e5c-4ef1-9ea3-37ae943c4980  Claim in safety — inconclusive  working
      ├─ used  claim/e13411da-8308-4928-94a7-658869556618  Claim in neuroscience — inconclusive  working
      ├─ used  claim/e4c7e980-2f28-48bd-a52a-79e04210ce68  Claim in neuroscience — inconclusive  working
      ├─ used  claim/6d3c6fea-ef0b-4578-80dc-a01f740a85df  Claim in chemistry — inconclusive  working
      ├─ used  claim/be665dd3-40e9-4752-a97c-052985a7d88a  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/7db9b889-2922-4b82-86bc-86b14e2cf5b8  Claim in neuroscience — inconclusive  working
      ├─ used  claim/b5f51fd1-6d4d-419f-aee3-f56e907b3e70  Claim in chemistry — inconclusive  working
      ├─ used  claim/4a5ccbd0-7e62-4913-b4f9-6272ed386712  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/47275404-8226-4a65-a1c8-a10e9f210b0c  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/9f55d1a0-7c0d-42ca-a1d6-cf88cdb54c5c  Claim in safety — inconclusive  working
      ├─ used  claim/a137fcd8-6b6c-490a-baca-943707973e04  Claim in chemistry — inconclusive  working
      ├─ used  claim/824ffc9c-814a-4ceb-b822-ddaa30b72cff  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/fbbfaecb-bf41-49b6-afec-03ba1d4e2916  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/00bff88a-477d-4023-ac2c-9bee34108a8b  Claim in safety — inconclusive  working
      ├─ used  claim/b7bfece1-b698-46f8-b479-2791a89ce3e7  Claim in chemistry — inconclusive  working
      ├─ used  claim/75afdc98-64d6-4b38-b4dc-78e0ae034255  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/bdc6ed8b-e0fb-4f76-90a5-c5f4aabf6a6a  Claim in pharmacology — inconclusive  working
      ├─ used  claim/800d272c-f956-4cac-9f1e-97460d86fa6e  Claim in pharmacology — not_supported  working
      ├─ used  claim/ebbf0b7b-8f75-4761-a069-30913862373f  Claim in pharmacology — inconclusive  working
      ├─ used  claim/eb24b712-0949-4473-b813-e764214e820a  Claim in pharmacology — inconclusive  working
      ├─ used  claim/b0af96c3-388e-4107-8d19-b86d842a07d5  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/87e251e4-9848-4824-9405-47a5b86136ef  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/ff4bf955-01a0-458e-aefb-cd56bf9a2617  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/28123f32-820f-4274-82a2-57d89d705142  Claim in pharmacology — inconclusive  working
      ├─ used  claim/2723c0b0-67fd-4299-981b-d8e5bb29af7c  Claim in pharmacology — inconclusive  working
      ├─ used  claim/d2952417-7f98-44a7-9d77-c0bfa1e3e6a0  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/9c4822a3-b44f-400d-837a-a0af9a224cb5  Claim in pharmacology — inconclusive  working
      ├─ used  claim/55fd3fa5-0f97-49b5-97c6-cc36e6085a5d  Claim in pharmacology — inconclusive  working
      ├─ used  claim/b53d6845-3a92-4d8e-92c7-f7c9cabcf98d  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/c569d8e6-022b-484d-8ccc-fceb0fadc7bf  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/f60cfe68-68de-4e24-8100-5705a35c1139  Claim in pharmacology — inconclusive  working
      ├─ used  claim/5c03fd74-3f1e-4abc-8919-60c08e7bd329  Claim in pharmacology — inconclusive  working
      ├─ used  claim/df323a2e-08d4-4b1e-9b32-c89af4c269a6  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/0b31f5df-773f-4354-b30c-202a77287119  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/f155750c-0d72-4d3f-8550-2b9142b7a6d1  Claim in pharmacology — inconclusive  working
      ├─ used  claim/e805fe60-f52b-42da-8748-788f437c767e  Claim in pharmacology — inconclusive  working
      ├─ used  claim/27bbbdcd-1f4c-464a-a741-494e4a560302  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/6a09585f-6e67-483f-803e-6f2c7dabf7b4  Claim in pharmacology — inconclusive  working
      ├─ used  claim/b555af10-8f6d-4532-be61-24d3068c0635  Claim in pharmacology — inconclusive  working
      ├─ used  claim/0c0866eb-c5c4-46d1-a393-5f5d3e7b7fe9  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/02a26b8d-4ab5-435a-88b9-e111d3288679  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/8bf3f358-7288-42f1-a2a2-4fe3ec3c1812  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/86a6031d-5d08-4136-bcb9-2493e5ecf55f  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/eafa7bd3-df1a-4999-8815-4d52a7ccfef0  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/a53962de-6e92-41ea-99c5-60d26fde0d60  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/aa4a740a-7f4c-4a98-aa1e-7c3ca5ba7d0c  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/c5253eb2-6fa5-475d-bae1-0536611b669e  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/a89641c5-de29-4c28-b506-f53b238d7c8e  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/3c1af64f-3a14-426e-80da-0a31cd57828f  Claim in safety — inconclusive  working
      ├─ used  claim/c5bc6fac-c38b-48ac-86fd-fd4e245d8c27  Claim in safety — inconclusive  working
      ├─ used  claim/1b308060-7f95-4d01-8a36-4502fa61a043  Claim in safety — inconclusive  working
      ├─ used  claim/85a3647c-6a00-481e-ae8d-f48916dfe9f1  Claim in safety — inconclusive  working
      ├─ used  claim/e64887f1-787b-4130-822f-677f9580b249  Claim in safety — inconclusive  working
      ├─ used  claim/54ab8fd2-2f06-45a5-ae56-7c0248915dc2  Claim in safety — inconclusive  working
      ├─ used  claim/5fa14997-1c98-454a-9e3e-4b309be25a3d  Claim in safety — inconclusive  working
      ├─ used  claim/28c13dcf-57a2-41c2-a7ba-1563e29982ce  Claim in safety — inconclusive  working
      ├─ used  claim/8cd66537-d46c-447a-bd5a-92ab9fc0b84d  Claim in safety — inconclusive  working
      ├─ used  claim/fe7131cf-f212-4e3e-a2d4-e0fa552f944b  Claim in safety — inconclusive  working
      ├─ used  claim/df866eed-91f6-4aef-a03c-921abeaad08d  Claim in safety — inconclusive  working
      ├─ used  claim/1dfadfa3-b43d-4c3f-b61b-bd485f15b6ca  Claim in safety — inconclusive  working
      ├─ used  claim/9520312d-5df4-43d8-80ad-fe94f51f6569  Claim in safety — supported
      ├─ used  claim/a056cc0b-4b95-4b46-be4e-900fc246acc5  Claim in safety — supported
      ├─ used  claim/b8837467-afb3-4f5d-a776-29564302497c  Claim in safety — inconclusive  working
      ├─ used  claim/c1e8748f-439a-459c-bd02-cabf75c6d543  Claim in safety — inconclusive  working
      ├─ used  claim/d69fab61-c5b3-49bc-85f3-c164c5a24534  Claim in safety — inconclusive  working
      ├─ used  claim/0b234520-9a59-480f-91e6-c656085178c5  Claim in safety — inconclusive  working
      ├─ used  claim/1539fe68-f9ca-40a9-9d5c-52a888536ff6  Claim in safety — inconclusive  working
      ├─ used  claim/90339679-9868-44c7-9114-506b752dd369  Claim in safety — inconclusive  working
      ├─ used  claim/81570f30-caee-4ddb-b3fe-92e3ce87c9d8  Claim in safety — inconclusive  working
      ├─ used  claim/ab693680-e589-471f-a297-71735c9bed36  Claim in safety — inconclusive  working
      ├─ used  claim/f01a7d50-10fb-4227-bfb7-8a572cf21003  Claim in safety — inconclusive  working
      ├─ used  claim/73b6a396-0444-4ce9-8fe2-145db33b390a  Claim in safety — inconclusive  working
      ├─ used  claim/b50b66ca-8301-465b-82c6-aded54eb32c9  Claim in safety — inconclusive  working
      └─ used  claim/1e8a4b8f-f4d6-4688-baf4-e0d21c684a35  Claim in safety — inconclusive  working
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2923 with DOI

3 strong · 12 moderate · 14 weak

Compilations

12026-05-08T13:29:43.706Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

28last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:34:25.337Z

notice · info card · emergency

Searches

182 with no results

queries and counts on the build

Claims checked

1584 supported

4 supported · 154 not

Correspondence

0received

consent field ships in Phase 4

Edges

404

derivations recorded for this entity

Complete over 29 sources, 1 compilation, and 28 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/u-47700/archive

2Build

one panel per compilation run

generation run 2026-05-08

70 min completedmodel pipeline-v5plan not recordedrun/b9562ed2…

Selection

results seen97

selected by the model40

consumed as sources29

Verification

claims checked158

supported2

partially supported2

not supported1

inconclusive153

record
seen / partial
working

The model's own caveats

sparse_evidence
structural_inference
safety_data_unverified

Reproduce

inputs: 29 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

18 searches — query, source, results, what was kept and why

18 searches for this run
#	source	query	seen	kept	rationale
1	PubChem	U-47700	1	1	Primary chemical identity verification
2	PubMed	U-47700 forensic postmortem blood concentration fatality	7	7	All provide key postmortem toxicology data for U-47700
3	ClinicalTrials.gov · absence	U-47700	0	0	Expected — U-47700 is a Schedule I controlled substance with no approved therapeutic use
4	PubMed	U-47700 overdose death case report toxicology	5	5	Direct case reports and forensic series on U-47700 fatalities
5	PubMed	U-47700 opioid pharmacology receptor binding	5	5	All directly relevant to U-47700 pharmacology and receptor binding
6	OpenAlex	U-47700 synthetic opioid pharmacology toxicology	10	3	Highly cited reviews with substantive U-47700 coverage
7	Web	U-47700 Ki binding affinity mu opioid receptor nM radioligand	10	1	Key pharmacological data points
8	PubMed	U-47700 analytical method detection urine blood screening	5	4	All provide validated analytical methods and metabolic data
9	Web	U-47700 DEA Schedule I emergency scheduling 2016 Federal Register	10	3	Primary regulatory documentation
10	UNODC	U-47700 substance details	1	1	Verified chemical identity and international scheduling
11	ClinicalTrials.gov · absence	U-47700	0	0	Confirms absence of clinical trial program
12	Web	U-47700 legal status UK Canada Australia New Zealand	10	3	International scheduling documentation
13	PubMed	U-47700 pharmacodynamics pharmacokinetics rat Ki binding	1	1	Primary quantitative PK/PD source with binding affinity data
14	Web	U-47700 Szmuszkovicz Upjohn patent 1978	10	1	Primary discovery documentation
15	Web	U-47700 CYP3A4 CYP2B6 FMO3 metabolism N-demethylation human liver microsomes	10	2	CYP enzyme identification for metabolism section
16	PubMed	U-47700 synthesis Upjohn benzamide opioid history 1970s	1	1	Definitive review paper; covers >40 year history
17	Web	U-47700 Prince death opioid toxicology 2016	10	1	Significant public health event linked to U-47700
18	CDC MMWR	U-47700 deaths fentanyl analogs 10 states 2016	1	1	Key epidemiological data source

158 claims by section — every cited sentence, checked against its source

safety46 · 2 ok

Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A multi-drug fatality combining 3-fluorophenmetrazine, U-47700, amitriptyline, methamphetamine, and two designer benzodiazepines (flubromazolam, delorazepam).supported
Polydrug fatality case involving flubromazolam and delorazepam among other NPS. Cause of death: multiple drug toxicity. bkx060
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Benzodiazepines: Multiple fatal cases document co-ingestion of designer benzodiazepines (flubromazolam, diclazepam) and classical benzodiazepines (alprazolam) with U-47700. Benzodiazepines augment respiratory depression through GABAergic potentiation of brainstem depression. This combination is documented as directly lethal.supported
Polydrug fatality case involving flubromazolam and delorazepam among other NPS. Cause of death: multiple drug toxicity. bkx060
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →

pharmacology24 · 1 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — not_supportednot supportedworking →
Full MOR agonism has been confirmed by GTPγS functional assay, where U-47700 produces maximal stimulation comparable to reference MOR agonists (DAMGO, fentanyl)partially supported
Morphine used as reference: butyrylfentanyl, U-47700, and MT-45 have nM affinities at MOR-1, less potent than morphine at MOR, much weaker at DOR and KOR. Morphine MOR potency reference in GTPγS assay. j.neuropharm.2017.08.016
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →

history22 · 0 ok

Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →

pharmacokinetic-detail16 · 0 ok

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

receptor-pharmacology12 · 0 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

summary12 · 1 ok

Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
It functions as a full MOR agonist through canonical Gαi/o signaling, confirmed by GTPγS functional assays and complete reversal of all effects by naloxone.partially supported
Morphine used as reference: butyrylfentanyl, U-47700, and MT-45 have nM affinities at MOR-1, less potent than morphine at MOR, much weaker at DOR and KOR. Morphine MOR potency reference in GTPγS assay. j.neuropharm.2017.08.016
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →

chemistry10 · 0 ok

Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →

comparative-pharmacology8 · 0 ok

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

neuroscience6 · 0 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →

clinical-evidence2 · 0 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →

3Sources

29 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
year	source	tier	status	feeds
2025	Rat-to-human PBPK model of U-47700: Unveiling pharmacokinetic risks of a synthetic opioid through interspecies extrapolationZhong L, Li L, He Q, Zhu X, Xiang P, Xiang X, Yan H · Toxicology and Applied Pharmacologydoi:10.1016/j.taap.2025.117352	moderate	consumed	2 sections
2024	Clinical Pharmacokinetics and Pharmacodynamics of NaloxoneSaari TI, Strang J, Dale O · Clinical Pharmacokineticsdoi:10.1007/s40262-024-01355-6	strong	consumed	1 section
2023	Development of a vaccine against the synthetic opioid U-47700Park H, Lin M, Zhou J, Eubanks LM, Zhou B, Janda KD · Frontiers in Pharmacologydoi:10.3389/fphar.2023.1219985	moderate	consumed	3 sections
2023	In silico characterization of ligand-receptor interactions for U-47700, N,N-didesmethyl-U-47700, U-50488 at mu- and kappa-opioid receptorsLaus A, Kumar A, Caboni P, De Luca MA, Baumann MH, Pieroni E, Tocco G · Archiv der Pharmaziedoi:10.1002/ardp.202300256	moderate	consumed	1 section
2022	Characterization of recent non-fentanyl synthetic opioids via three different in vitro mu-opioid receptor activation assaysVandeputte MM, Persson M, Walther D, Vikingsson S, Kronstrand R, Baumann MH, Gren H, Stove CP · Archives of Toxicologydoi:10.1007/s00204-021-03207-9	moderate	consumed	2 sections
2020	Challenges Related to Three Cases of Fatal Intoxication to Multiple Novel Synthetic OpioidsGarneau B, Desharnais B, Beauchamp-Dore A, Lavallee C, Mireault P, Lajeunesse A · Journal of Analytical Toxicologydoi:10.1093/jat/bkz018	weak	consumed	1 section
2020	DARK Classics in Chemical Neuroscience: U-47700Kyei-Baffour K, Lindsley CW · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.0c00330	moderate	consumed	4 sections
2020	Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7	strong	consumed	1 section
2020	Multiplex detection of 14 fentanyl analogues and U-47700 in biological samples: Application to a panel of French hospitalized patientsJung J, Kolodziej A, Pape E, Bisch M, Javot L, Gibaja V, Jouzeau JY, Scala-Bertola J, Gambier N · Forensic Science Internationaldoi:10.1016/j.forsciint.2020.110437	moderate	consumed	1 section
2020	Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male ratsTruver MT, Smith CR, Garibay N, Kopajtic TA, Swortwood MJ, Baumann MH · Neuropharmacologydoi:10.1016/j.neuropharm.2020.108195	moderate	consumed	7 sections
2019	Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700Richeval C, Gaulier JM, Romeuf L, Allorge D, Gaillard Y · International Journal of Legal Medicinedoi:10.1007/s00414-018-1969-3	weak	consumed	2 sections
2019	Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drugFels H, Lottner-Nau S, Sax T, Roider G, Graw M, Auwaerter V, Musshoff F · Forensic Science Internationaldoi:10.1016/j.forsciint.2019.04.010	weak	consumed	3 sections
2019	To Test or Not To Test?: The Value of Toxicology in a Delayed Overdose DeathWalsh EE, Shoff EN, Zaney ME, Hime GW, Garavan F, Boland DM · Journal of Forensic Sciencesdoi:10.1111/1556-4029.13822	weak	consumed	1 section
2019	Toxic lifespan of the synthetic opioid U-47,700 in Finland verified by re-analysis of UPLC-TOF-MS dataKriikku P, Pelander A, Rasanen I, Ojanpera I · Forensic Science Internationaldoi:10.1016/j.forsciint.2019.04.030	weak	consumed	2 sections
2018	Analysis of fentanyl analogs and novel synthetic opioids in blood, serum/plasma, and urine in forensic caseworkMoody MT, Diaz S, Shah P, Papsun D, Logan BK · Drug Testing and Analysisdoi:10.1002/dta.2393	moderate	consumed	1 section
2018	Another fatal case related to the recreational abuse of U-47700Strehmel N, Dumpelmann D, Vejmelka E, Strehmel V, Roscher S, Scholtis S, Tsokos M · Forensic Science, Medicine, and Pathologydoi:10.1007/s12024-018-0018-3	weak	consumed	3 sections
2018	Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug usersKrotulski AJ, Mohr ALA, Papsun DM, Logan BK · Drug Testing and Analysisdoi:10.1002/dta.2228	moderate	consumed	2 sections
2018	Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplaceBaumann MH, Majumdar S, Le Rouzic V, et al. · Neuropharmacologydoi:10.1016/j.neuropharm.2017.08.016	moderate	consumed	3 sections
2017	A Fatality Related to the Synthetic Opioid U-47700: Postmortem Concentration DistributionMcIntyre IM, Gary RD, Joseph S, Stabley R · Journal of Analytical Toxicologydoi:10.1093/jat/bkw124	weak	consumed	1 section
2017	An Expanding World of Novel Psychoactive Substances: OpioidsZawilska JB · Frontiers in Psychiatrydoi:10.3389/fpsyt.2017.00110	strong	consumed	4 sections
2017	Canada Gazette: Regulations Amending Schedule I to the Controlled Drugs and Substances Act (U-47700)Health Canadaurl:05303be8251da6e6	weak	consumed	cited only
2017	Circular 008/2017: A change to the Misuse of Drugs Act 1971 to control U-47700UK Home Officeurl:2f5b38eeb1243fa6	weak	consumed	cited only
2017	Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016.O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM · MMWR. Morbidity and mortality weekly reportdoi:10.15585/mmwr.mm6643e1	moderate	consumed	1 section
2017	Multiple Drug-Toxicity Involving Novel Psychoactive Substances, 3-Fluorophenmetrazine and U-47700Ellefsen KN, Taylor EA, Simmons P, Willoughby V, Hall BJ · Journal of Analytical Toxicologydoi:10.1093/jat/bkx060	weak	consumed	1 section
2017	Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid classSchneir A, Metushi IG, Sloane C, Benaron DJ, Fitzgerald RL · Clinical Toxicologydoi:10.1080/15563650.2016.1209764	weak	consumed	1 section
2017	UNODC Substance Details: U-47700 (CID 237db0fd)UNODC Laboratory and Scientific Sectionurl:3fdc70b47ed3951e	weak	consumed	cited only
2016	Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC-MS/MS in Postmortem CaseworkMohr AL, Friscia M, Papsun D, Kacinko SL, Buzby D, Logan BK · Journal of Analytical Toxicologypmid:27590036	weak	consumed	2 sections
2016	DEA Schedules Deadly Synthetic Drug U-47700 - Press ReleaseDrug Enforcement Administrationurl:45a13c74420c2964	weak	consumed	cited only
2016	Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I. Final orderDEA Administrator · Federal Registerpmid:27905978	moderate	consumed	1 section
—	Searched ClinicalTrials.gov for "U-47700" — no resultsabsence		no results	—

Show all 31 sources — 1 more

Sources 31 to 31
year	source	tier	status	feeds
—	Searched ClinicalTrials.gov for "U-47700" — no resultsabsence		no results	—

4Docket

one filing per activity — decisions, correspondence, reports

0012026-05-08revisionRevision 1
Initial LLM generation (v5 pipeline, wiki, prose phase)
psx:substance/u-47700/version/1
0022026-06-04proposal26 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
26 items in this filing
- contraindication · other
- contraindication · hepatic
- contraindication · other
- contraindication · pregnancy_breastfeeding
- contraindication · other
- dose_tier · threshold
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · insufflated · onset
- timeline · insufflated · come_up
- timeline · insufflated · peak
- timeline · insufflated · resolution
- timeline · insufflated · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · insufflated
- duration · insufflated · onset
- duration · insufflated · come_up
- duration · insufflated · peak
- duration · insufflated · total
- duration · insufflated · aftereffects
psx:substance/u-47700/proposal/contraindication/5336b6ce-a858-4d68-a027-b309adc00ae3
0032026-06-04publicationPublication — backfill
psx:substance/u-47700/pub/34b1532c-3460-4f78-ba6b-65cf0090b547

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
info_card	f4a704e0ac55e6b5c7d54f28…	2026-10-19 20:34	Revision 1	current
emergency	f85b2d2362c98030e2585598…	2026-09-04 04:32	Revision 1	current
info_card	0335bca422f8cbf5bd54828c…	2026-09-04 04:32	Revision 1	superseded2026-10-19
notice	de80e261c2b4a6c467864993…	2026-09-04 04:32	Revision 1	current

U-47700

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-05-08

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify